The Latest Breaking News from Gilead

JPMorgan's upgrade on Gilead sparks bullish sentiment for the healthcare sector—here's why stocks like Pfizer and Hims & Hers are promising opportunities.

Trump’s proposed tariffs on pharmaceutical imports from countries like Ireland and India have sparked concerns for companies like Amgen and Gilead Sciences.

The UNAIDS director also warned that US funding cuts could be dire for global efforts to curb HIV.

The world risks returning to the worst days of the global AIDS pandemic following the sudden halt to US foreign aid funding, the UN's top AIDS official said Monday, warning millions would die.

The head of the U.N. AIDS agency says the sudden loss of American money has been “devastating” for efforts to stop HIV and will cost many lives of the world’s most vulnerable people

Gilead stock tumbled Wednesday on reports HHS could slash federal funding for HIV prevention, a staple in Gilead Sciences' topline.

Summary Gilead Sciences (GILD) shows strong technical buy signals, with a 19.60% gain since Trend Seeker's buy signal on 1/27 and a 50.31% gain in the last year. The company offers a diverse portfolio of medicines for HIV, COVID-19, liver diseases, oncology, and more, with significant collaborations enhancing its pipeline....

As Gilead Sciences has outperformed its industry peers recently, Wall Street analysts maintain a moderately optimistic outlook on the stock’s prospects.

Gilead Pharmaceuticals is back to highs not seen in a decade as its HIV treatment franchise surges and awaits its 100% effective HIV prevention drug in summer

The Handmaid's Tale season 6 returns to Hulu on April 8 – here's everything we know about the dystopian drama's return.

Gilead stock surged to a buy zone Wednesday after the company obliterated fourth-quarter forecasts and issued an upbeat profit outlook.